Modalities of use of ceritinib (Zykadia (TM)), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer

作者：Leprieur Etienne Giroux; Fallet Vincent; Wislez Marie^*

来源：Bulletin du Cancer, 2015, 102(12): 1053-1057.

DOI：10.1016/j.bulcan.2015.09.007

• Non-small cell lung cancer
• ALK rearrangement
• Ceritinib

Around 4% of advanced non-small cell lung cancers (NSCLC) harbor a ALK rearrangement, with high sensitivity to ALK inhibitor as crizotinib. However, the vast majority of these tumors end with a tumor progression after several months of treatment with crizotinib. Ceritinib is a 2nd generation ALK inhibitor, which showed high efficiency in NSCLC with ALK rearrangement. Results from phase I trial showed a response rate at 58% in these tumors, with a similar rote for previously crizotinib-treated patients or crizotinib-naive patients. Moreover, cerebral responses were observed with ceritinib. Preliminary date from a phase 2 trial confirmed these results. These promising results allowed a European marketing authorization (autorisation de mise sur le marche [AMM]) since May 2015 for the treatment of advanced NSCLC with ALK rearrangement and resistance or intolerance to crizotinib.

• 出版日期2015-12